Stromectol is the brand name historically associated with prescription oral ivermectin tablets in the United States. Unlike a generic ingredient name, Stromectol identifies a specific branded drug product and its regulatory history. The U.S. brand labeling describes 3 mg tablets for certain parasitic infections, but a label or an old product listing cannot establish whether a pharmacy can obtain the branded product today. This page explains what the brand name signifies, how its strengths have been represented in U.S. records, and why current availability must be confirmed separately from FDA approval or historical labeling.
A particularly important distinction concerns 6 mg tablets. FDA records identify Merck’s branded Stromectol 6 mg as no longer marketed in the United States, while an FDA-approved generic ivermectin 6 mg product exists under a separate application. Discontinuation of the original 6 mg brand was not attributed by FDA to safety or effectiveness. This does not mean that every ivermectin 6 mg listing is discontinued, nor does generic approval demonstrate stock at a particular pharmacy. For a broader account of the tablet category, see oral ivermectin products.
Someone searching for Stromectol may be trying to identify the original brand, interpret a prescription written with a brand name, or understand why a pharmacy offers generic ivermectin instead. Those questions are related but not identical to the transaction itself. Use the generic ivermectin overview to examine the generic product category and the Stromectol versus generic comparison for a direct brand-and-generic evaluation. A licensed pharmacist can clarify the specific product being dispensed and whether a brand request can be fulfilled.
Stromectol is a proprietary name for ivermectin tablets intended for oral administration in humans. The name should not be used as a synonym for every ivermectin preparation sold in the United States. Prescription oral tablets, prescription ivermectin cream for rosacea, and nonprescription ivermectin lotion for head lice are distinct dosage forms with different labels and routes of use. Stromectol refers to the oral brand, not to those topical products or to ivermectin formulations made for animals.
A prescription may identify a drug by its brand or by the generic ingredient, and the exact directions, strength and other requirements must still be followed. A pharmacy record can show the name Stromectol even when a generic product is ultimately dispensed, depending on the prescription, applicable substitution rules and what the pharmacy is able to supply. The name on a search result, a product photograph or an older catalog entry should therefore be distinguished from the actual drug selected for a prescription fill.
The useful identifiers are the product name, dosage form, strength, prescription directions and specific labeling for the dispensed item. Brand recognition by itself says nothing about the appropriateness of treatment or whether a product is currently stocked. Readers who need to understand strength-specific tablet details can consult ivermectin 3 mg product information rather than assuming a familiar brand description identifies every generic package.
A U.S. Stromectol label revised in September 2024 describes oral 3 mg tablets and supplies historical product-identification information for that strength. This establishes what the labeling states; it does not independently establish the manufacturer’s current distribution plans or a pharmacy’s inventory. A listing in a drug-label database and an actively fillable retail item are not the same thing, so statements such as “Stromectol is available everywhere” would be unsupported.
The branded Stromectol 6 mg product has a different, documented status. In its January 2025 generic approval correspondence, FDA stated that Merck’s reference-listed Stromectol 6 mg tablets were no longer marketed in the United States and appeared in the discontinued section of the Orange Book. FDA also stated that the withdrawal was not for safety or effectiveness reasons. “Discontinued” in this regulatory context should not be misread as a finding that the 6 mg molecule or strength is unsafe, and it should not be applied automatically to a separately approved generic product.
FDA approved generic ivermectin tablets in both 3 mg and 6 mg strengths under ANDA 215922 in January 2025. The generic 6 mg approval does not revive the old branded 6 mg product, and it does not prove that generic packs are on a particular pharmacy shelf. The dedicated ivermectin 6 mg product page addresses the 6 mg approval and strength-specific product details. A patient with a prescription should ask the dispensing pharmacy about the exact approved item rather than extrapolating from older brand catalogs.
Brand status is easiest to understand when FDA approval, the product label and retail availability are treated as separate questions. FDA’s application and Orange Book records speak to approved products and marketing classifications. DailyMed reproduces submitted drug labeling, including product and packaging details. A dispensing pharmacy, meanwhile, must determine what is actually orderable for the relevant prescription at the time of the inquiry.
The following comparison focuses on the documented distinctions rather than trying to maintain a live stock table. References to strengths or historical status are not recommendations to choose or change a dose. The pharmacist and prescribing clinician remain responsible for determining what product, if any, may be supplied under the prescription.
| Product reference | Documented U.S. position | What the record does not prove | Related product question |
|---|---|---|---|
| Stromectol 3 mg brand | A U.S. Stromectol label describes 3 mg oral prescription tablets. | That the branded tablets are currently orderable or stocked by a specific pharmacy. | How the 3 mg tablet is identified |
| Stromectol 6 mg brand | FDA identifies the Merck reference brand 6 mg as no longer marketed in the U.S.; not withdrawn for safety or effectiveness. | That a historical branded 6 mg package is currently available to purchase. | How the discontinued brand relates to generics |
| Generic ivermectin 3 mg | FDA-approved generic tablets exist with separate product and labeling identifiers. | That every generic labeler or package is presently in distribution. | How generic tablets are identified |
| Generic ivermectin 6 mg | FDA approved 6 mg generic tablets under ANDA 215922 in January 2025. | That the product is in stock or that a brand 6 mg product has returned. | What the 6 mg generic approval establishes |
The U.S. Stromectol 3 mg label describes a white, round, flat, beveled tablet marked “MSD” on one side and “32” on the other. The September 2024 labeling includes the NDC identifiers 0006-0032-20 and 0006-0032-01 for labeled 3 mg unit-dose presentations. These are examples of what a documented brand label contains, not a list of confirmed retail inventory. Packaging records can be revised, and an NDC describes a labeled drug-package identity rather than a universal statement about current supply.
A pharmacy may dispense tablets in a patient-labeled container rather than the manufacturer’s full outer carton. Generic ivermectin tablets may differ in appearance, imprint, labeler, inactive ingredients or supplied packaging from the Stromectol presentation. An unfamiliar-looking tablet is not automatically counterfeit, just as a photograph matching an older brand label is not proof that a seller is legitimate. The dependable comparison is between the dispensed pharmacy label, the actual tablet and the pharmacist’s verified product information.
Before using a newly dispensed medication, confirm the patient name, drug name, strength, prescription instructions and any applicable storage information on the pharmacy label. If the strength, imprint or quantity seems inconsistent, pause and have the pharmacy investigate. Do not identify medication from internet photographs alone, transfer tablets into an unlabeled container or rely on an unfamiliar overseas package as if it were a U.S.-approved Stromectol product.
U.S. Stromectol labeling identifies two parasitic infections: intestinal strongyloidiasis caused by Strongyloides stercoralis and onchocerciasis caused by Onchocerca volvulus. These labeled indications do not imply effectiveness against all parasites, every type of skin condition or every illness for which the word ivermectin appears in an online advertisement. A clinician must evaluate the condition, available diagnostic information and the suitability of oral therapy before prescribing.
Oral ivermectin is also used off-label in certain clinical circumstances, including some cases of scabies. Off-label prescribing is a decision made by a licensed clinician; it is not an additional FDA-approved indication and cannot be promised by an internet seller. The distinct ivermectin for scabies overview provides context for that clinical use without turning this brand page into a regimen guide. The brand name does not justify self-treatment or switching from a different prescribed medication.
Ivermectin is not approved or authorized by FDA to prevent or treat COVID-19. Veterinary ivermectin products are not equivalent to human prescription tablets and must not be substituted. Questions about the intestinal infection indication can be explored in the strongyloidiasis information page. Brand labeling is the foundation for understanding what the original drug was approved to treat, not a shortcut to deciding whether someone should take it.
A generic prescription drug is evaluated against a reference-listed product for the applicable strength and dosage form. FDA approval of an abbreviated new drug application involves requirements for sameness of active ingredient and other pharmaceutical characteristics, as well as evidence supporting bioequivalence and therapeutic equivalence. In the 2025 approval of ANDA 215922, FDA explicitly identified Stromectol 3 mg and 6 mg as the corresponding reference-listed products. This is an approval relationship, not proof of currently marketed branded units in both strengths.
Substitution decisions in a retail pharmacy depend on the prescription, the approved product, applicable state law and other relevant conditions. A prescriber may specify a brand, while the pharmacy may need to clarify whether an approved generic is permitted or preferable under the prescription. Differences in shape, imprint, packaging or certain inactive ingredients do not necessarily mean a generic fails FDA equivalence criteria. Conversely, the shared ingredient name does not make different strengths and dosage forms interchangeable without an appropriate prescription decision.
The direct Stromectol-versus-generic comparison covers the head-to-head questions of equivalent products, branding and pharmacy substitution in greater depth. On this page, the essential point is that an approved generic tablet may be a distinct currently marketed product even when its historical reference brand has a different market status. A pharmacist can explain which product the prescription and pharmacy process support.
If a prescription or old medication record names Stromectol, ask the pharmacy to confirm whether the request refers to the original brand or to an ivermectin generic. Pharmacy staff can clarify how the prescription is written, whether a specific brand is required, whether a therapeutically equivalent product is permitted and which strength is listed. They can also distinguish a product that exists in a database from one their wholesaler can actually supply. None of these questions requires changing or selecting a dose independently.
It may be helpful to ask whether the pharmacy can verify the manufacturer or labeler, National Drug Code and dispensing format before a fill. If the requested brand is not orderable, the pharmacist may need to contact the prescriber about an appropriate approved alternative, subject to applicable laws and the clinical circumstances. A catalog entry is not a promise that the medication is on hand, and a pharmacy should not be expected to provide a discontinued branded 6 mg product merely because the name remains familiar.
A local pharmacy visit has its own practical considerations: prescription receipt, insurance processing, pharmacist consultation and pickup. Those steps are explained in the local ivermectin pharmacy guide. For the broader sequence from a valid prescription to a legal purchase, consult U.S. prescription-pharmacy options. Brand identification and current supply remain separate issues even after the prescription and purchasing requirements are understood.
A listed Stromectol price may refer to a historical brand item, a generic substitute or an outdated catalog record. The amount ultimately charged for a valid fill depends on the specific product, quantity, pharmacy and payment arrangement. Brand-versus-generic differences can affect cost, but neither the name of the brand nor an old advertised price establishes what a patient will pay. The separate Stromectol price guide explains evergreen cost factors without treating temporary offers as permanent facts.
Insurance coverage is also product-specific. A plan may have a formulary preference, utilization requirements or different patient costs for brands and generics; none of those details can be presumed without checking the actual benefit. Some apparent “Stromectol” search results may point to foreign products or sellers who cannot lawfully fill a U.S. prescription. The presence of a brand logo, a product photograph or an attractive quoted price is not a substitute for confirming pharmacy licensing and prescription requirements.
When using an internet pharmacy, verify the seller through appropriate U.S. licensing channels and ensure that a valid prescription and pharmacist support are required. The dedicated online-pharmacy verification guide covers those checks. To understand how insurance may change out-of-pocket costs without relying on stale quotes, read ivermectin insurance coverage. Do not assume that a brand-specific offer represents authorized U.S. supply or that a cheaper listing guarantees the correct human-use product.
Stromectol is a prescription human medicine. It should be used only for a condition and regimen evaluated by a licensed clinician, with the actual dispensing instructions followed. The label includes precautions and potential adverse effects, and people should tell their clinician and pharmacist about other medications, relevant medical conditions and any prior reaction to ivermectin. Medication-safety questions cannot be resolved simply by deciding that a familiar brand is preferable to a generic.
A person who is pregnant, breastfeeding, taking interacting medicines or managing significant underlying illness needs advice appropriate to their circumstances. Possible neurologic symptoms, severe allergic reactions or other serious concerns warrant prompt medical attention. The general ivermectin safety overview discusses the broader safety context, while the actual prescriber and pharmacist remain responsible for patient-specific guidance. This page intentionally does not provide a dosing chart or recommend a treatment course.
Finally, oral Stromectol is not the same drug product as ivermectin cream 1% for rosacea or ivermectin lotion 0.5% for head lice, and veterinary formulations should never be used as human substitutes. If a prescription was issued but the intended brand is unavailable, the next step is to discuss an appropriate FDA-approved human product with the pharmacy or prescribing clinician—not to obtain a different form or strength based on an internet search. Regulatory approval, clinical appropriateness and practical supply are three separate questions.
Stromectol is a U.S. brand name for prescription oral ivermectin tablets. The name identifies a specific branded product and labeling history, rather than every drug containing ivermectin. Generic oral tablets and topical ivermectin products have their own product identities and should be evaluated separately.
The U.S. brand label describes Stromectol 3 mg tablets, but the existence of labeling does not confirm present-day retail stock. FDA specifically identifies the original branded Stromectol 6 mg as no longer marketed. Ask a licensed pharmacist whether the relevant brand product is currently orderable and what approved alternatives may be available.
No. FDA has stated that Merck’s branded Stromectol 6 mg was not withdrawn from sale for reasons of safety or effectiveness. The historical brand discontinuation should be distinguished from FDA approval of a separate generic ivermectin 6 mg product.
No. FDA approval of a generic 6 mg tablet is an approval for that generic product. It does not restart marketing of the discontinued Stromectol 6 mg brand or guarantee that any pharmacy stocks the generic.
The U.S. Stromectol labeling revised in September 2024 describes 3 mg prescription tablets. Historic regulatory records also reference branded 6 mg tablets, but that brand strength is listed as no longer marketed in the United States. Tablet strength is product-identification information, not advice on what dose a patient needs.
They contain the same active ingredient when comparing corresponding oral ivermectin products. FDA-approved generics must meet applicable pharmaceutical and bioequivalence requirements, while appearance, packaging and certain inactive ingredients may differ. A pharmacist should verify the specific approved strength and whether substitution is allowed for the prescription.
It may be possible when the prescription, approved product, applicable state substitution law and any prescriber restrictions permit. A pharmacy should determine whether an appropriate generic can be dispensed. A patient should not change the prescribed strength or substitute another dosage form independently.
The U.S. labeling identifies intestinal strongyloidiasis and onchocerciasis. Other clinical uses, including some treatment of scabies with oral ivermectin, are off-label and require a clinician’s assessment. FDA has not approved or authorized ivermectin to prevent or treat COVID-19.
Compare the prescription and pharmacy label with the dispensed tablet’s strength and identifying information. The U.S. brand labeling describes a 3 mg tablet marked MSD and 32, but appearances and packages must be verified against the specific item supplied. If anything does not match, ask the dispensing pharmacist before taking it.
The pharmacy may be unable to order the requested brand, or an approved generic may be permitted under the prescription and applicable rules. Insurance coverage and product supply can also influence the options discussed. The pharmacist should clarify the exact product, strength, prescription requirements and any proposed substitution before dispensing.